Blog
RSS FeedPosted by Michael Wonder on 14 Aug 2017
NICE turns down kidney cancer drugs
14 August 2017 - It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will ...
Posted by Michael Wonder on 09 Aug 2017
NICE supports the use of another treatment option for patients with renal cell carcinoma on the NHS
9 August 2017 - NICE has completed its appraisal of cabozantinib maleate for patients with previously treated advanced renal cell ...
Posted by Michael Wonder on 09 Aug 2017
NICE publishes final guidance for baricitinib
9 August 2017 - NICE has published final guidance on the use of baricitinib for the treatment of patients with ...
Posted by Michael Wonder on 09 Aug 2017
NICE recommends Erbitux
8 August 2017 - NICE recommends Erbitux in combination with platinum-based chemotherapy for the treatment of recurrent and/or metastatic head and ...
Posted by Michael Wonder on 09 Aug 2017
Thousands more people could be offered drugs to prevent bone fractures because of osteoporosis
9 August 2017 - NICE has published new guidance on the use of drugs called bisphosphonates for preventing bone fractures in ...
Posted by Michael Wonder on 06 Aug 2017
NICE issues draft guidance on Almirall’s Skilarence for psoriasis
4 August 2017 - NICE, the cost-effectiveness watchdog for England, has issued draft guidance recommending Skilarence (dimethyl fumarate). ...
Posted by Michael Wonder on 04 Aug 2017
NICE leans towards a ‘no’ for Keytruda in urothelial cancer
4 August 2017 - Cost regulators for NHS therapies in England and Wales have turned down MSD’s immunotherapy Keytruda as ...
Posted by Michael Wonder on 04 Aug 2017
Pancreatic cancer patients to have routine access to life extending drug after new deal, says NICE
4 August 2017 - NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and ...
Posted by Michael Wonder on 03 Aug 2017
UK finds Roche bladder cancer drug too costly for routine use
3 August 2017 - Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to ...
Posted by Michael Wonder on 03 Aug 2017
Negative NICE draft guidance for Lutathera
3 August 2017 - UK medicines cost-effectiveness watchdog NICE has today published draft guidance which does not recommend French molecular nuclear ...
Posted by Michael Wonder on 31 Jul 2017
NICE bars obesity pill from routine NHS use
31 July 2017 - Cost regulators for NHS treatments in England and Wales are standing by their position that Orexigen’s ...
Posted by Michael Wonder on 27 Jul 2017
£3 a day drug for irritable bowel syndrome gets NICE approval
27 July 2017 - The drug, Truberzi has been recommended for routine funding on the NHS to treat patients with irritable ...
Posted by Michael Wonder on 26 Jul 2017
Roche hails 4 year NICE access deal for Gazyvaro
26 July 2017 - NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the ...
Posted by Michael Wonder on 26 Jul 2017
NICE approval for nivolumab provides new treatment for advanced blood cancer
26 July 2017 - People with an advanced type of blood cancer will benefit from nivolumab on the NHS following approval ...
Posted by Michael Wonder on 25 Jul 2017
Vismodegib for treatment of patients with basal cell carcinoma
20 July 2017 - The Department of Health has asked the NICE to produce guidance on the use vismodegib in the ...